AXSM peer analysis
Axsome Therapeutics (AXSM) against its competitors: price, today's move, 1-year return and market value side by side.
AXSM and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AVXL Anavex Life Sciences | $1.19 | -8.46% | -85.18% | $110.31M |
| DFTX Definium Therapeutics | $32.96 | -9.28% | – | – |
| DNLI Denali Therapeutics | $18.82 | -0.63% | 14.90% | $3.03B |
| JAZZ Jazz Pharmaceuticals | $216.38 | 0.19% | 58.76% | $14.02B |
| NBIX Neurocrine Biosciences | $146.37 | 0.18% | 6.03% | $14.85B |
| NMRA Neumora Therapeutics | $0.37 | -5.43% | -87.47% | – |
| PRAX Praxis Precision Medicines | $276.07 | -3.45% | 37.35% | – |
| RAPP Rapport Therapeutics | $24.55 | -1.98% | -8.65% | – |
| SUPN Supernus Pharmaceuticals | $41.92 | 0.19% | -25.81% | $2.44B |
| XENE Xenon Pharmaceuticals | $38.02 | 1.63% | -10.90% | $3.62B |
| AXSM Axsome Therapeutics | $132.66 | -8.15% | -0.37% | $7.57B |
- AXSM's peers: AVXL (Anavex Life Sciences), DFTX (Definium Therapeutics), DNLI (Denali Therapeutics), JAZZ (Jazz Pharmaceuticals), NBIX (Neurocrine Biosciences), NMRA (Neumora Therapeutics), PRAX (Praxis Precision Medicines), RAPP (Rapport Therapeutics).
Updated 2026-11-02 18:27 UTC